The clinical outcomes associated with masked hypertension defined by home blood pressure monitoring (HBPM) in clinical settings remain uncertain.
C linic blood pressure (BP) may not accurately reflect the BP levels that patients experience in their daily environment outside the clinic (eg, at home, at work, and during sleep). [1] [2] [3] [4] Of importance, 30% to 50% of patients with hypertension whose BP levels appear well controlled when measured in a clinical setting have high BP outside the physician's office. [5] [6] [7] [8] This phenomenon of hypertension in which the diagnosis is missed in a clinical setting is known as masked hypertension. 9,10 Masked hypertension confers a 2-fold higher risk of cardiovascular disease (CVD) compared with normotension both in and out of the clinic.
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For out-of-clinic BP measurements, 2 techniques have been developed: ambulatory BP monitoring (ABPM) and home BP monitoring (HBPM). [2] [3] [4] The standard method for diagnosing masked hypertension is ABPM. However, ABPM has constraints, including the limited availability and affordability of monitoring devices and low tolerability by examinees as a result of sleep disturbances, discomfort, and restrictions in daily activities. 2, 14 Compared with ABPM, HBPM is more acceptable and better tolerated by examinees.
14 Increasing evidence shows that, in community-based populations, adverse cardiovascular outcomes are associated with masked hypertension defined by HBPM. 12, 15 However, little is known regarding the outcomes associated with masked hypertension in clinical settings. Masked hypertension is associated with cardiovascular end-organ damage (ie, albuminuria and cardiac hypertrophy). 12, [16] [17] [18] [19] Therefore, masked hypertension may confer an increased risk of CVD events only because it reflects the presence or severity of cardiovascular end-organ damage. However, few studies have investigated whether the CVD risk associated with masked hypertension is independent of the extent of cardiovascular end-organ damage. We are uniquely positioned to address this gap in knowledge by using data from the Japan Morning Surge-Home Blood Pressure (J-HOP) study. 20 The J-HOP study enrolled outpatients with history of or risk factors for CVD and conducted HBPM in the morning and evening during a 14-day period. We examined the following: (1) the association between masked hypertension and CVD events and (2) whether the association is independent of the extent of cardiovascular end-organ damage, including the urine albumin to creatinine (Cr) ratio (UACR) and the circulating brain (or B-type) natriuretic peptide (BNP) level.
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Methods
Study Design
The rationale, design, and procedures of the J-HOP study have been published previously (eMethods in the Supplement).
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Briefly, 4310 outpatients with history of or risk factors for CVD were enrolled between January 1, 2005, and December 31, 2012 , from 71 primary practices or university hospitals throughout Japan. The participants were followed up through March 31, 2015.
The institutional review board of Jichi Medical University School of Medicine (Shimotsuke, Japan) approved the methods of the J-HOP study. All of the patients provided written informed consent to participate and to have their data published. The present study was conducted to fulfill one of the overall aims of the J-HOP study and used the preexisting data set from the study. Thus, the institutional review board of Jichi Medical University School of Medicine did not require a separate approval for this analysis.
BP and Other Measurements
The J-HOP study methods are described in the eMethods in the Supplement. Three clinic BP readings were taken at 15-second intervals on 2 different occasions, and the mean of the 6 readings was defined as the clinic BP level. Self-measured home BP levels were obtained according to the Japanese BP guideline. 23 Three home BP readings were taken at 15-second intervals, with patients in a seated position in both the morning (within 1 hour of waking and before taking antihypertensive medication) and the evening (before going to bed) for 14 consecutive days. The first day's home BP measurements were excluded, and the mean (SD) of the remaining morning (35.1 [7.2] readings) and evening (33.3 [8.2] readings) BP levels were calculated separately. The clinic and home BP levels were obtained using the same validated, automatic, and oscillometric device (HEM-5001; Omron Healthcare). 24 To prevent reporting bias, BP data were automatically stored in the memory of the device and were downloaded to a computer by a physician or nurse during the clinic visits. Laboratory methods are described in the eMethods in the Supplement. The spot UACR and plasma BNP levels were assessed at baseline. Diabetes mellitus was defined as selfreported history of a physician's diagnosis, diabetes medication use, or a fasting blood glucose level of 126 mg/dL or higher or a nonfasting glucose level of 200 mg/dL or higher (to convert glucose levels to millimoles per liter, multiply by 0.0555). History of CVD events, including angina pectoris, myocardial infarction, and stroke, was ascertained at baseline. The characteristic attitude and symptoms of depression in 4001 participants were evaluated using the Beck Depression Inventory (BDI) test, 25 and sleep duration in 3772 participants was evaluated using a questionnaire.
Definition of BP Groups
or evening. Morning home BP levels were associated with adverse cardiovascular outcomes, whereas evening home BP levels were not. Therefore, only morning home BP levels were used to define the 4 BP groups (masked hypertension group, white-coat hypertension group, sustained hypertension group, and controlled BP group). Masked hypertension was defined as hypertensive home BP levels (systolic BP [SBP], ≥135 mm Hg; diastolic BP [DBP], ≥85 mm Hg) and nonhypertensive clinic BP levels (SBP, <140 mm Hg; DBP, <90 mm Hg), whitecoat hypertension was defined as nonhypertensive home BP levels (SBP, <135 mm Hg; DBP, <85 mm Hg) and hypertensive clinic BP levels (SBP, ≥140 mm Hg; DBP, ≥90 mm Hg), sustained hypertension was defined as hypertensive home and clinic BP levels, and controlled BP was defined as nonhypertensive home and clinic BP levels. In a secondary analysis, we used morning and evening home BP levels to define the 4 BP groups.
Ascertainment of Outcomes
Each participant's vital status was ascertained through March 31, 2015. Incident CVD events during follow-up, including coronary heart disease (CHD) (fatal and nonfatal coronary artery disease and sudden death within 24 hours of the abrupt onset of symptoms) and stroke (fatal and nonfatal), were assessed as outcomes. The J-HOP study 20 reported that a higher home BP level was associated with an increased risk for stroke but not for CHD. Therefore, stroke and CHD were evaluated separately. If events occurred on 2 or more occasions, the first occurrence was included in the analysis. Cardiovascular disease events were ascertained by ongoing reports from a general physician at each participating institution. Follow-up time was censored on the data of event ascertainment. Participants who did not experience CVD events were censored at the final study visit. Additional details are given in the eMethods of the Supplement.
Statistical Analysis
Data were analyzed from July 1, 2017 , to October 31, 2017 We conducted sensitivity analyses by (1) using the mean morning and evening home BP levels to define the 4 BP groups and (2) considering home and clinic BP levels (as a continuous variable) jointly in stroke or CHD prediction models. This approach allowed us to assess whether home BP levels have a stronger association with stroke or CHD events compared with clinic BP levels. Two-sided P < .05 was statistically significant. All statistical analyses were performed with R, version 3.3.1 (The R Foundation for Statistical Computing) and SAS, version 9.4 (SAS Institute Inc).
Results
Among the 4310 participants, 32 participants who were lost to follow-up and 17 patients who had missing UACR or BNP data were excluded, leaving a sample of 4261 participants for analysis ( Table 1 4 [10.3-43.3 ] pg/mL) (to convert BNP levels to nanograms per liter, multiply by 1.0).
The incidence rate of stroke or CHD events and the KaplanMeier cumulative incidence were determined by the 4 BP groups (Table 2 and Figure 2 ). During a median (IQR) follow-up of 3.9 (2.4-4.6) years (16 875 person-years), 74 stroke (4.4 per 1000 person-years) and 77 CHD (4.6 per 1000 person-years) events occurred. The masked hypertension group had a higher incidence rate of stroke events compared with the controlled BP group (5.4 per 1000 person-years; 95% CI, 3.4-8.5 vs 1.7 per 1000 personyears; 95% CI, 0.9-3.4). Conversely, the incidence rate of CHD was similar across the groups.
With adjustments for covariates, results from the Cox proportional hazards regression models suggested that both the masked (HR, 2.66; 95% CI, 1.15-6.13) and sustained (HR, 3.43; 95% CI, 1.61-7.30) hypertension groups had a greater risk for stroke compared with the controlled BP group (model 2; Table 2 ). We further adjusted for UACR and circulating BNP levels, and the results were similar (model 3; masked hypertension group HR, 2.77; Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BNP, brain (or B-type) natriuretic peptide; BP, blood pressure; Cr, creatinine; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; J-HOP, Japan Morning Surge-Home Blood Pressure study; SBP, systolic blood pressure; UACR, urine albumin to Cr ratio.
SI conversion factors: To convert glucose levels to millimoles per liter, multiply by 0.0555; total cholesterol and HDL-C levels to millimoles per liter, multiply by 0.0259; and BNP levels to nanograms per liter, multiply by 1.0.
a Holm correction for multiple comparisons was used to compare characteristics among the groups. Kruskal-Wallis test was used to compare differences in UACR and BNP across the 4 BP groups, and the Steel-Dwass test was used for post hoc multiple comparisons. Statistical significance was defined as P < .05.
b P < .05 vs controlled BP group. c P < .05 vs white-coat hypertension group.
d P < .05 vs masked hypertension group.
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Association of Cardiovascular Outcomes With Masked Hypertension in a Japanese General Practice Population 95% CI, 1.20-6.37 vs sustained hypertension group HR, 3.34; 95% CI, 1.56-7.13). Masked and sustained hypertension yielded no association with CHD events (Table 2) . White-coat hypertension yielded no association with stroke or CHD events. When the 4 BP groups were defined by the mean morning and evening home BP levels, the results were similar (eTable 2intheSupplement). We adjusted for sleep duration (eTable 3i nt h eSupplement) and BDI test scores (eTable 4 in the Supplement), and the results were similar.
When clinic and home SBP levels (as continuous variables) were analyzed jointly, only home SBP levels (HR, 1.52; 95% CI, 1.22-1.89) were associated with stroke risk (Table 3) . Neither clinic nor home SBP and DBP levels were associated with CHD risk.
Discussion
In this nationwide, practice-based study of 4261 Japanese with history of or risk factors for CVD, we demonstrated that masked hypertension defined by HBPM (vs nonhypertensive BP level in the clinic and home) was associated with (1) greater cardiovascular end-organ damage, including UACR and circulating BNP levels, and (2) an increased risk for stroke events independent of the extent of cardiovascular end-organ damage. The magnitudes of cardiovascular end-organ damage and stroke risk in the masked hypertension group were intermediate between those of the controlled BP and sustained hypertension groups. Masked hypertension was not associated with CHD risk. White-coat hypertension yielded no association with stroke or CHD events.
The hypertension was not associated with CVD risk in IDHOCO participants taking antihypertensive medication.
In the present study, we extend these findings by demonstrating that, among middle-aged and older Japanese being treated for hypertension and/or other cardiovascular risk factors, (1) the masked hypertension group had a higher risk for stroke events compared with the controlled BP group (ie, nonhypertensive BP level in the clinic and home) and a similar risk as the sustained hypertension group, and (2) the white-coat hypertension group had a risk for stroke or CHD events similar to that of the controlled BP group. Analyses including home and clinic SBP levels jointly (as a continuous variable) supported the conclusion that home SBP levels were associated with stroke risk, whereas clinic SBP levels were not.
Cross-sectional association between masked hypertension defined by HBPM and cardiovascular end-organ damage, including albuminuria and cardiac hypertrophy, has been demonstrated. 12, 18 Baseline cardiovascular end-organ damage was not assessed in the SHEAF 11 and IDHOCO 15 studies.
Therefore, whether masked hypertension is a potential contributor to adverse cardiovascular events or merely an epiphenomenon of cardiovascular damage remains to be determined. Modeling adjustments for UACR and circulating BNP levels did not materially change our present findings, but possible residual confounders may have affected the masked hypertension-stroke risk association. Sodium intake, lower socioeconomic status, job strain, psychosocial stress (eg, anxiety disorders and anger), and greater BP level variability could be associated with both masked hypertension and incident stroke events. [34] [35] [36] [37] [38] [39] [40] Whether the increased stroke risk of masked hypertension was solely attributable to home BP level elevation is unclear. Unraveling the mechanistic links between masked hypertension and adverse outcomes will require further investigation.
In the present study, masked hypertension conferred no CHD risk. This finding is consistent with a previous report from the J-HOP study indicating that home SBP and DBP levels were not associated with CHD events. 20 The previous masked hypertension studies using HBPM did not evaluate risk associations by distinct cardiovascular outcomes (ie, CHD and stroke, separately). 11, 12, 15 However, the IDHOCO study reported that home SBP levels were associated with an increased risk for stroke but not CHD events in participants taking antihypertensive medications. 41 Conversely, higher home SBP levels were Log rank, P <.001 Log rank, P =.75
Figure 2. Four Blood Pressure (BP) Groups and Cardiovascular Disease Events
Kaplan-Meier curves of the cumulative incidence of stroke (A) or coronary heart disease (CHD) (B) by the 4 BP groups are shown. 
Strengths and Limitations
The strengths of this study include its nationwide scope, the application of standard clinic and home BP measurements, and the high patient retention rate. However, the study has limitations. First, because this was an observational study, we were unable to determine causality in the findings. Second, 79.2% of our recruited patients were taking antihypertensive medication, and we were unable to assess the association between outcomes and the changes in BP phenotypes and the use of antihypertensive medication during follow-up. Hypertension treatment based on clinic and home BP levels is recommended for all Japanese physicians. 23, 45, 46 These factors could potentially dilute any true association between each BP phenotype and stroke or CHD risk.
Third, we defined masked hypertension using home BP levels in the morning. In this study, CVD risk associated with masked hypertension appeared to be attenuated when we defined masked hypertension using the mean morning and evening home BP levels. We did not include midday BP level in defining masked hypertension. It remains uncertain whether clinical outcome associated with masked hypertension differs when defined using morning, midday, and evening home BP measurements vs morning home BP level alone. How HBPM should be performed to better identify the masked hypertension group at high risk for CVD events merits further investigation. Fourth, we evaluated UACR and circulating BNP levels as a marker of cardiovascular endorgan damage. However, UACR and circulating BNP levels may not accurately reflect the extent of cardiovascular end-organ damage. Further studies are warranted to investigate whether the association between masked hypertension and stroke risk is independent of rigorous cardiovascular end-organ damage markers, including brachial-ankle pulse wave velocity and left ventricular mass index on echocardiography. Fifth, our findings may not be generalizable to other racial/ethnic groups.
Conclusions
An increased stroke risk may be associated with masked hypertension defined by HBPM in the Japanese general practice population. Masked hypertension could be missed if out-of-clinic BP level is not evaluated. Home BP monitoring may emerge as a complementary prevention and treatment strategy in clinical practice and could help reduce the public health burden of CVD. Further studies are warranted to assess whether reductions in home BP level can help prevent CVD events among individuals with masked hypertension. This hypothesis will need to be confirmed in interventional trials, with consideration of all of the complex issues at play, including costeffectiveness and patient perspectives. The adjusted HR (95% CIs) associated with each BP group is shown. Adjusted factors for Model 2 included the 4-year cardiovascular risk scores, comprising demographic variables (age and sex) and clinical and behavioral characteristics (body mass index; smoking status; prevalence of diabetes; pre-existing angina pectoris, myocardial infarction, or stroke; total cholesterol; high-density lipoprotein cholesterol; and statin or antihypertensive medication use), log-transformed UACR, and log-transformed BNP. Adjustment factors for Model 3 included sleep duration and the 4-year cardiovascular risk scores, comprising demographic variables, clinical and behavioral characteristics, log-transformed UACR, and log-transformed BNP. Statistical significance was defined as P<0.05. HR indicates hazard ratio; CI, confidence interval; BP, blood pressure; CHD, coronary heart disease; UACR, urine albumin-to-creatinine ratio; BNP, brain natriuretic peptide.
© 2018 American Medical Association. All rights reserved. Number of stroke events, (per 1,000 person-years; 95% CIs) 6, (1.4; 0.6-3.0) 3, (1.3; 0.4-3.8) 15, (5.1; 3.1-8.5) 37, (6.0; 4.3-8.2) Model 1 (unadjusted) The adjusted HR (95% CIs) associated with each BP group is shown. Adjusted factors for Model 2 included the 4-year cardiovascular risk scores, comprising demographic variables (age and sex) and clinical and behavioral characteristics (body mass index; smoking status; prevalence of diabetes; pre-existing angina pectoris, myocardial infarction, or stroke; total cholesterol; high-density lipoprotein cholesterol; and statin or antihypertensive medication use), log-transformed UACR, and log-transformed BNP. Adjustment factors for Model 3 included the BDI test score and the 4-year cardiovascular risk scores, comprising demographic variables, clinical and behavioral characteristics, log-transformed UACR, and log-transformed BNP. Statistical significance was defined as P<0.05. HR indicates hazard ratio; CI, confidence interval; BP, blood pressure; CHD, coronary heart disease; UACR, urine albumin-to-creatinine ratio; BNP, brain natriuretic peptide; BDI, Beck Depression Inventory.
